Our People

Dr. Bowden joins Remix from Agios, where he served as a Strategic Advisor and Chief Medical Officer (CMO) from 2014-2022. As CMO he oversaw clinical development that led to US approvals for the IDH inhibitors IDHIFA and TIBSOVO in AML, for TIBSOVO in cholangiocarcinoma and for PYRUKYND, a Pyruvate Kinase activator, for adults with Pyruvate Kinase Deficiency. Prior to joining Agios, Dr. Bowden was vice president product development oncology, franchise lead (Signaling Group) at Genentech, Inc. where he was responsible for the successful development of several novel targeted oncology medicines, including Zelboraf™ and Tarceva™. Before that, Dr. Bowden was the executive director for EMEA regions for Bristol-Myers Squibb where he led medical affairs strategies for cancer, immunology and pain medicines. Earlier, Dr. Bowden held positions of increasing responsibility in oncology clinical development at Pharmacia Corporation and Janssen Pharmaceutical, Inc. Prior to his industry work, Dr. Bowden was on the oncology faculty at the University of Virginia Health Science Center. Dr. Bowden received his M.D. from Hahnemann University School of Medicine in Philadelphia after which he completed his internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He conducted his medical oncology fellowship at the National Cancer Institute Medicine Branch. Dr. Bowden is board certified in internal medicine and medical oncology.

Silvia brings more than 15 years of drug discovery and translational research experience to Remix. She joins from Monte Rosa Therapeutics where she served as Senior Vice President focusing on discovering molecular glue degraders for oncology and beyond. Silvia held positions of increasing responsibility at the Novartis Institute of Biomedical Research and H3 Biomedicine where she led the discovery and development of three small molecules: the smoothened antagonist, LDE225 (Sonidegib), the allosteric Bcr-Abl inhibitor, ABL001 (Asciminib) and the splice modulator, H3B-8800. Afterwards, she helped build several companies at Third Rock Ventures and Atlas Venture before joining Monte Rosa Tx.
Silvia received her Ph.D. from the University of Bologna in Applied Genetics with a focus on studying the biology of multiple myeloma, acute and chronic myeloid leukemias, after which she conducted postdoctoral studies at the University of Illinois at Chicago and the University of Chicago/New York University on a variety of oncology-centric projects.

Rob brings more than 20 years of financial and commercial experience leading global finance operations. Prior to his appointment, Rob served as an Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund. Earlier, he was Chief Business Officer and Chief Financial Officer at Verastem Oncology. Before that, he was Chief Financial Officer at Harvard Bioscience, Inc. Prior to this, he served as Executive Vice President, Chief Financial Officer, and Treasurer at Clean Harbors, Inc. as well as Chief Accounting Officer and Controller at Biogen Idec, Inc. Earlier, he worked in a variety of senior positions at Deloitte & Touche, LLP, and PricewaterhouseCoopers, LLP. He holds an M.B.A. from the MIT Sloan School of Management and a B.A. in Accounting from Bentley College. Rob currently serves on the Board of Directors at Verastem Oncology and Purple Biotech.

Zaven is Chief Scientific Officer of Remix Therapeutics. He brings extensive research and drug discovery experience, as well as deep domain expertise in Neuroscience to the team.  Most recently, he was a venture partner at the Dementia Discovery Fund managed by SV Health Investors, where he focused on company creation.  Prior to that he was a director of neuroscience research at Amgen in Cambridge, MA, and managed teams tasked with developing new therapeutics for neurodegenerative disorders and chronic pain.  Before joining industry, he was a faculty member at the Albert Einstein College of Medicine directing a research group investigating the molecular mechanisms underlying axon guidance and dendrite branching in the developing spinal cord and brain.  Zaven received his PhD from The Johns Hopkins University and carried out postdoctoral training at the California Institute of Technology. He is excited about Remix’s unique approach of manipulating RNA processing for therapeutic benefit in a variety of indications.

As head of chemistry, Dominic is stoked to be a part of building Remix from the ground up, leading the design and synthesis of compounds to reprogram RNA processing and forge a path to the clinic. Dominic has extensive experience in the biotech space and building successful biotech companies. Recent positions include drug discovery consultancy to two seed-stage companies at Third Rock Ventures and VP, Head of Chemistry at H3 Biomedicine, a company he joined on day one. Prior to that Dominic worked at Forma Therapeutics, where he also joined on the first day, and he started his career at Millennium Pharmaceuticals. He received his PhD in synthetic chemistry from the University of Cambridge and conducted postdoctoral training at Harvard University where he focused on natural product synthesis.

Mark has more than 25 years of Human Resources experience working in a number of smaller organizations driving the organizational evolution to grow the business. He brings a wealth of global and cultural expertise having worked and lived abroad for many years. He most recently worked at Codiak BioSciences as part of the HR team, and spent ten years at Hologic as Vice President Human Resources for the International Division. He holds a BS Degree from the University of Rhode Island, and he has many years of non profit board work most recently with the Horace Mann Educational Association.

Pete is Co-Founder, President and Chief Executive Officer of Remix Therapeutics. Prior to Remix, he was Chief Scientific Officer at H3 Biomedicine, a precision oncology company, where he oversaw discovery, non-clinical development, translational research and clinical biomarkers. He was previously at Takeda and Millennium Pharmaceuticals where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. He received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute. Pete also sits on the Board of Directors of Ryvu Therapeutics and is an advisor to several drug discovery companies.

Fred oversees the biomolecular sciences, screening and lead discovery effort at Remix Therapeutics. He joins the team with more than 15 years of experience in a range of roles in drug discovery, most recently serving as a consultant for Third Rock Ventures. Prior to that, Fred held various leadership roles at H3 Biomedicine and Boehringer Ingelheim. Now, Fred is motivated to push the current boundaries of drug discovery with the Remix team. He received his PhD in biochemistry and molecular biology from the University of British Columbia and completed his postdoctoral training as a Merck-sponsored Helen Hay Whitney Foundation fellow at Harvard Medical School.

Heather is responsible for corporate business development and operations at Remix. She joins after 7 years at Eli Lilly, where she gained extensive business knowledge while heading up immunology search and evaluation, emerging technologies and innovations and most recently global corporate business development during her tenure there. Heather received a PhD from the University of Georgia, and went on to complete a postdoctoral fellowship at Emory University. Heather is excited to work alongside Remix’s talented team focused on novel small molecule modulation of RNA processing.

Jennifer activates people and teams to develop and deliver impactful medicines. Empowered with perspective and skill from twenty years of strategic execution, Jennifer joined Remix to build and lead Clinical Development Operations and Patient Engagement. Prior to Remix, Jennifer led and contributed to the development, launch, and commercialization of numerous genomically driven therapeutics and diagnostics, most notably seven first-in-class products for rare diseases and oncologic malignancies. Jennifer’s accomplishments are diverse and broad. Her achievements span global efforts in Clinical Operations, Program Leadership, Alliance Management, and Business Operations at leading organizations such as Vertex, Takeda, Foundation Medicine, and Fulcrum Therapeutics. Jennifer earned her Bachelor’s degree in Psychology at the University of Rochester and an MBA from the University of Massachusetts.

Scott is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates. Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb. During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. Scott earned a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.

Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Navitor Pharmaceuticals. He is a co-founder and board member of Disc Medicine and is chair of the board of Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin completed his PhD in genetics at Harvard Medical School.

Jeff Goater is a Venture Partner at The Column Group. He is also interim Chief Executive Officer of Atavistik Bio. Previously, Jeff served as Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme. Previously he spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy. Jeff holds master’s degrees in microbiology/immunology (M.S.), pathology (M.S.) and business administration (M.B.A.) from the University of Rochester.

Matt Patterson is biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition by Astellas Pharma Inc. in January 2020. Matt was also Chairman of the Board of Directors and formerly served as President until May 2018. Previously he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is a member of the Board of Directors of Homology Medicines, Inc., Vor Biopharma, Inc., Remix Therapeutics, Inc., and 5:01 Acquisition Corporation. He is also a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He served as Chairman of ARM in 2019 and 2020.  Matt received his Bachelor’s degree in Biochemistry from Bowdoin College.

Michael joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his PhD in biochemistry from Caltech as an NSF graduate research fellow and has more than 12 years of experience as a research scientist, having authored numerous publications in biomedical research journals.

Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. Peter currently leads fundraising, strategy, hiring and other tasks at Remix while also directing all scientific activities. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Peter received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.